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Background/Aims.20Kilodalton-hGH(20K-hGH)isthesecondmostabundantpituitaryGHvariantafter22K-hGH.Inthesteady
state the proportion of 20:22K-hGH appears constant; does this proportion change with repetitive somatotroph stimulation?
Methods. Forty adult males were randomised to receive a GHRH(1–29)NH2 bolus (0.5µg/kg (n = 20) or 1.0µg/kg (n = 20)),
preceded or followed by a saline bolus, 1 week apart. Four to six weeks later, 10 subjects received 0.5µg/kg GHRH(1–29)NH2 at 0,
60, 120, and 180 minutes. Clearance rate of 22 and 20K-hGH was measured in 10 subjects. Results. Total amount/proportion of
22K-hGH/20K-hGH secreted was similar for both GHRH(1–29)NH2 doses. Repetitive stimulation reduced the amount of 22K-
hGH released whereas the amount of 20K-hGH did not change signiﬁcantly leading to an increase in the proportion of 20K-hGH
(P = .05). Half-life of 20 and 22K-hGH were not signiﬁcantly diﬀerent (P = .55). Conclusions. Repetitive stimulation of the
somatotroph may alter the proportion of GH variant released.
1.Introduction
Growth-hormone-releasing hormone (GHRH) acts on the
GHRH receptor in the pituitary gland to alter the rate of
GH gene transcription, increasing the amount of growth
hormone produced and released [1]. GH secretion occurs
immediately following a GHRH pulse, with the amount of
GH released in response to an intravenous bolus dependent
bothondoseofGHRHandonhowfrequentlythepituitaryis
stimulated with GHRH. Two main forms of GH account for
most of the GH released in response to GHRH stimulation
[2, 3], 22K-hGH (191 amino acids) (approximately 75% of
total secretion) and 20K-hGH (176 amino acids) (5–10%)
[4]. Numerous other forms are also detectable [5].
The 20K-hGH version lacks residues 32–46 as a result of
alternate splicing within exon 3, but retains high biological
activity on the GH receptor. It may bind less tightly to the
extracellular domain of the GH receptor, but appears to
have the same eﬃcacy at the full length receptor [6]. The
physiological importance of the diﬀerent isoforms of GH in
humans remains unclear as sensitive and speciﬁc immunoas-
says for 20K-hGH have only been recently developed [7]. 22
and 20K-hGH have almost identical somatogenic activity in
prepubertal male and female dwarf rats [8], but this reﬂects
interaction with rodent receptors which diﬀer from human
GH receptor.
It is not known what controls the ratio of splicing
of 20 versus 22H-hGH products in the pituitary, and
whether they are stored as eﬃciently, but when secretion is
studied, the 22K:20K-hGH ratio remains constant when
measured over a 24 hour period and following exercise
[9]. In children the percentage of the 20K-hGH isoform
remains constant independent of age, sex, puberty, height,
body mass index, and rate of GH production [10]. These
observations have led to the suggestion that the overall
production of 20K-hGH is under the same regulation as2 International Journal of Pediatric Endocrinology
that of 22K-hGH. However, recent in vitro studies using
transgenicmicepituitarycelllineshavespeciﬁcallyaddressed
therelativesplicingeﬃcienciesofGHproductsinthecontext
of mutations that alter the usage of splice donor/acceptor
sites in favour of a dominant negative 17.5K-hGH form
in which exon 3 sequences are completely eliminated [11].
In this case, driving synthesis and production in an in
vitro system altered the relative amounts of alternately splice
products made. We have, therefore, evaluated the impact of
repetitive stimulation with GHRH in humans, a stimulus
that also directly drives GH synthesis, on the amount of
20:22K-hGH produced.
2.SubjectsandMethods
2.1. Subjects. 40 adult male volunteers aged 19–25 years were
recruited to the study. All were of normal height (170–
182cm), weight (68–80kg), and body mass index (22.8–
24.4). None of the subjects smoked and alcohol was avoided
on the day before each study. Subjects fasted from midnight
prior to admission the following morning to the Clinical
Investigations Unit at 08.00h. An intravenous (iv) cannula
was placed in a forearm vein to allow blood sampling and
administration of iv bolus injections of GHRH(1–29)NH2
(Pﬁzer, Stockholm, Sweden). Subjects were allowed to rest
for 60 minutes before the study commenced. Exercise and
daytime napping were prohibited.
Study 1 (Dose and Intensity Studies). T h e4 0s u b j e c t sw e r e
randomized to receive either a GHRH(1–29)NH2 bolus
(0.5µg/kg (n = 20) or 1.0µg/kg (n = 20)), preceded or
followed by an IV bolus injection of saline. The two studies
were separated in time by an interval of 1 week (Study 1).
Ten of the subjects who originally received a 0.5µg/kg
GHRH(1–29)NH2 bolus were chosen at random to partic-
ipate in a second study. On a separate occasion, 4–6 weeks
after the dose studies, these individuals received 0.5µg/kg
GHRH(1–29)NH2 administered at 0, 60, 120, and 180
minutes, to determine within group and within individual
variation in response to GHRH(1–29)NH2 stimulation,
with the 20 and 22kDa responses 60 minutes after the
ﬁrst GHRH injection used to determine within group and
within individual variation in response to GHRH(1–29)NH2
stimulation (Reproducibility Study). Blood samples were
drawn at 10 minutes intervals for the measurement of serum
20 and 22K-hGH until 240 minutes. At the start of the study
an additional sample was drawn for the measurement of
insulin-like growth factor-1 (IGF-1). Samples were spun and
separated and the serum stored at −20◦C prior to assay.
Study 2 (Half-Life Study). Following Study 1, 10 further (i.e.,
diﬀerent) subjects chosen at random received a single iv
bolus injection of 0.5µg/kg GHRH(1–29)NH2 followed by
serial blood sampling to estimate the half life of endoge-
nouslyreleased20and22K-hGH.Thisstudywasundertaken
6–8 weeks after the completion of Study 1. In this study
an additional iv cannula was inserted in the contralateral
arm for infusion of Somatostatin (1–14) (Ferring Pharma-
ceuticals, Malmo, Sweden) (20µg/m2/hour). Blood samples
were drawn at 10 minutes intervals for the ﬁrst 60 minutes
following the bolus administration of GHRH(1–29)NH2.A t
this point the somatostatin (1–14) infusion was commenced
and blood samples drawn at 5 minutes intervals for the
following 90 minutes and assayed as in Study 1.
These studies were approved by the ethics committee’s at
University College London Hospitals and University College
London, and written informed consent obtained from the
subjects.
3.Assays
3.1. 20K-hGH Assay. 20K-hGH was measured by a triple
antibody ELISA. Microtitre plates were coated for 7 hours
at 37◦C with a 20K-hGH speciﬁc mouse monoclonal
antibody HGH33 in phosphate buﬀered saline (PBS) [12].
Prior to assay, nonspeciﬁc binding sites were blocked with
5% milk protein for 45 minutes. Standards and samples
were incubated in triplicate for 90 minutes, after which
a polyclonal sheep anti-hGH antibody (Scottish Antibody
Production Unit, Roslin, UK) was bound to the 20K-hGH33
complex. This was followed by the addition of a biotinylated
rabbit antigoat antiserum (DAKO Ltd., High Wycombe,
UK)whichrecognisessheepimmunoglobulins.Visualisation
used an avidin:biotin complex with alkaline phosphatase
as enzyme tracer (DAKO Ltd, High Wycombe, UK). The
plate was developed at 24◦C over 15–19 hours using p-
nitrophenylphosphate as substrate (Sigma-Aldrich Co. LTD,
Poole, UK) with the colour reaction measured at 405nm.
Recombinant methionyl-20K-hGH (Genentech, San
Francisco, CA, USA) (dissolved in adult human standard
matrix) was used as standard at concentrations up to
10ng/mL. The minimum detection limit of the assay
was 0.1ng/mL as determined by the mean of zero +
3SD, based on 25 repeat determinations. The within-
assay coeﬃcients of variance (CV) were 12% and 6.5%
at 2.8 and 7.0ng/mL, respectively. The between-assay CV
were 13.0% and 11.8% at 2.8 and 5.3ng/mL, respectively.
The ELISA showed no detectable cross reactivity with
recombinant22K-hGH(InternationalReferencePreparative
88/624; NIBSC, South Mimms, UK) at physiological con-
centrations (50–100ng/mL). At very high concentrations of
22K-hGH (10µg/mL) cross reactivity was 0.6%. At phys-
iological concentrations, pituitary-derived hGH standard
(International Standard 80/505; NIBSC) (50–100ng/mL)
showed3%-4%cross-reactivityinthe20K-hGHassay.There
was no cross reactivity at pathological concentrations of
hPRL(4000mU/L;NorthEastThamesRegionImmunoassay
Service, St Bartholomew’s Hospital, London, UK).
3.2. 22K-hGH Assay. Serum 22K-hGH was measured
using the Hybritech Tandem-R immunoradiometric assay
(Hybritech, Liege Belgium). This is highly speciﬁc for the
22K-hGH variant of hGH and showed no cross-reactivity
with 20K-hGH. The minimum detection limit of the assay
was 0.19ng/mL. The within-assay CV were 10.6%, 5.2% andInternational Journal of Pediatric Endocrinology 3
4.9%at0.5,5.5,and10.2ng/mL.Thebetween-assayCVwere
15.4%, 8.0%, and 6.3% at 1.6, 5.2, and 13.8ng/mL. The assay
was standardized against HS2243E (NIH, Bethesda, Mary-
land, USA) and has been recalibrated against International
Standard 80/505 (NIBSC, South Mimms, UK).
3.3. IGF-I Assay. IGF-I was measured by a commercial
immunoradiometric assay (Nichols Institute Diagnostics,
San Juan Capistrano, CA, USA). This is a nonextraction
method where IGF binding proteins are separated from the
IGF-I by acidiﬁcation of the sample and excess of IGF-II is
added to block the binding proteins from recombining with
the IGF-I. The within-assay CV were 4.6% and 3.3% at 6.1
and 292.5ng/mL, respectively. The between-assay CV were
15.5% and 11.3% at 88.6 and 240.4ng/mL. The standards
were prepared from recombinant IGF-I and calibrated
against International Reference Preparation 87/518 (NIBSC,
South Mimms, UK). The minimum detection limit of the
assay was 6ng/mL.
4. Statistics
All data were explored for the normality of their distribution
and when appropriate natural-log (Ln) transformed. For
this study, “total” GH refers to the sum of the 22 and
20K-hGH serum concentrations. The eﬀect of the dose of
GHRH(1–29)NH2 on the amount and proportion of the
GH isoforms was compared using paired Student’s t-test
as were the group data obtained from the stimulation tests
conducted on the two separate occasions 4–6 weeks apart.
One way Analysis of Variance (ANOVA) with a repeated
measures design was used for the study in which GHRH(1-
29)NH2 was administered thrice. The coeﬃcient of varia-
tion was estimated for the within individual variation for
percentage of 20K-hGH secreted in response to GHRH(1–
29)NH2 stimulation. Multiple linear regression was used to
exploretherelationshipbetweenthepercentageof20K-hGH
released and factors such as intensity of response. The half-
lives of 22 and 20K-hGH were determined using techniques
previously described by ourselves for GH [13].
5. Results
5.1. General. Data were available for all individuals who
participated in the dose study. Nine of the 10 subjects who
were selected for the triple GHRH(1–29)NH2 stimulation
study completed all three stimulation tests ((a) Saline, (b)
0.5µg/kg baseline, (c) 0.5µg/kg 4–6 weeks later at 0, 60,
120, and 180 minutes), (one individual only completed the
0 and 60 minutes time points in the triple GHRH(1–29)NH2
study).
Following the bolus injection of saline there was no
change in the serum 22 or 20K-hGH concentrations which
remained low and close to the detection limit of both assays.
In all studies both 22 and 20 K-hGH concentrations were
detectable above the lower limit of detection of the assay.
Serum IGF-1 concentrations were 300ng/mL (range 220–
375) in the individuals at the start of the study.
Table 1: Eﬀects of 0.5µg GHRH(1–29)NH2 stimulation in 10
subjects on two separate occasions (4–6 weeks apart) on 22,
20 kilodalton and percentage of 20 kilodalton human-growth
hormone secreted (concentrations measured 60 minutes after
administration of GHRH(1–29)NH2).
Study 1 Study 2
22K-hGH (ng/mL) 16.8 ± 2.7 19.2 ± 2.0
20K-hGH (ng/mL) 1.2 ± 0.3 1.9 ± 0.3
Percentage 20K-hGH 8.4 ± 2.4 9.8 ± 1.7
Data shown as mean and SEM.
5.2. Study 1. There was no signiﬁcant diﬀerence in the
peak response to diﬀerent doses of GHRH(1–29)NH2 in
the total amounts of 22K-hGH (mean peak 22K-hGH
to 0.5µg/kg GHRH(1–29)NH2 20.8 ± 3.4ng/mL and to
1.0µg/kgGHRH(1–29)NH2 22.3 ±2.3ng/mL;P = .37:20K-
hGH (2.6 ± 1.5 ng/mL and 2.2 ± 0.4ng/mL, respectively;
P = .71) or the proportion of 20K-hGH (10.7 ± 2.5% and
9.4 ± 1.6%, respectively; P = .66) secreted. However, the
higher the peak hGH concentration, irrespective of dose, the
greater the percentage of 20K-hGH was present (r = 0.31;
P = .04).
We tested the eﬀects of the GHRH(1–29)NH2 dose
administered as a single and then further bolus injections
and determined, the amounts and proportion of 20K-hGH
released. With more frequent stimulation the amount of
22K-hGHreleaseddecreasedsigniﬁcantly(OnewayANOVA
F = 16.4; P<. 001) whereas the amount of 20K-hGH
did not change signiﬁcantly, resulting in a net increase in
percentage of 20K-hGH present (F = 3.10; P = .05)
(Figure 1, Table 2 and Figure 2). By multiple regression
analysis (R = 0.29; P = .04) the intensity of response
to GHRH(1–29)NH2 was the major determinant of the
percentage of 20K-hGH present (B = 3.89, P = .02) with
a much lesser contribution from the total amount of hGH
released (B = 0.11, P = .11).
The within individual coeﬃcients of variation for 22K-
hGH, 20K-hGH, and the percentage of 20K-hGH secreted
following GHRH(1–29)NH2 administration on the two
o c c a s i o n sw e r e1 9 . 0± 4.4, 24.5 ± 9.2, and 20.5 ± 6.7%,
respectively. Group data were similar on the two occasions
with no signiﬁcant diﬀerences detected (Table 1).
5.3. Study 2. The initial half-lives of clearance of 22K-hGH
(14.2 ± 1.1 minutes) and 20K-hGH (15.7 ± 0.9 minutes)
were not signiﬁcantly diﬀerent (P = .55) in these subjects.
6. Discussion
These data demonstrate that the intensity of response to
GHRH(1–29)NH2 appears to be a more important determi-
nant of the amount of 20K-hGH released than the dose of
GHRH(1–29)NH2 administered. In response to a repeated
GHRH(1–29)NH2 stimulation lower total concentrations
of hGH were achieved and a higher percentage of 20K-
h G Hw a sp r e s e n t( Figure 1, Table 2 and Figure 2). These
ﬁndings have implications for clinical practice as many4 International Journal of Pediatric Endocrinology
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Figure 1:SerumGrowth-Hormoneconcentrations(22K-hGHand
20K-hGH) attained after repeat bolus intravenous administration
of 0.5µg GHRH(1–29)NH2. Data shown as mean and SEM.
Table 2: Absolute concentrations of 22K-hGH and 20K-hGH
attained after repeat bolus intravenous administration of 0.5µg
GHRH(1–29)NH2.
0 minute 60 minutes 120 minutes 180 minutes
22K (ng/mL) 22.3 19.2 10.4 4.4
20K (ng/mL) 2.2 2.5 1.4 0.7
endocrine centres measure peak 22K-hGH response to
two consecutive GH provocation tests to diagnose growth
hormone deﬁciency.
The overall eﬀect of GHRH(1–29)NH2 on total hGH
secretion was to reduce the concentrations achieved when
the stimulus was applied with an interval of 1, 2, or 3 hours
compared to the initial application of GHRH(1–29)NH2 a
ﬁnding consistent with the literature [14]. This eﬀect was
more marked for 22K-hGH than 20K-hGH. Our study
diﬀersfrompreviousreportsinthatwehaveusedaﬁxeddose
ofGHRH(1–29)NH2 andmeasuredtheconcentrationofGH
variants not only in the steady state but also in response to
intensive repeat stimulation [10]. We conﬁrm that in the
steady state with minimum stimulation the proportion of
20K-hGH found in the circulation accounts for approxi-
mately10%oftotal,andthatafterrepeatedstimulation20K-
hGH comprises 15.7% of total hGH released. Our ﬁndings
clarify previous reports which have also addressed the idea
that repeated stimulation may aﬀect the proportions of the
diﬀerent GH isoforms produced and released, but have been
unable to distinguish isoforms produced by splicing, from
other minor forms that can arise from fragmentation or
deamidation, included in “non-22K-hGH” isoforms present
[15].
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Figure 2: Percentage Serum 20kDa Growth-Hormone concen-
tration after repeat bolus intravenous administration of 0.5µg
GHRH(1–29)NH2. Data shown as mean and SEM.
The eﬀect of repeated stimulation with GHRH(1–
29)NH2 on the percentage of 20K-hGH present in the
circulation is unlikely to be materially aﬀected by diﬀerences
in the clearance of 20K-hGH as the measured disappearance
half-lives of 22K-hGH and 20K-hGH were similar in these
subjects. This does not rule out the possibility that there
could be diﬀerential binding to circulating growth hormone
binding proteins in the steady state, but this is less likely
to impact on our ﬁndings given the short-time frames over
which repeated stimulation was performed. It is more likely
that our results reﬂect diﬀerences in the ratio of 20 versus
22K-hGH products secreted under these conditions. In
addition to the factors altering splicing eﬃciency, diﬀerences
in protein stability, granule packaging, or secretion could
all contribute to these diﬀerences, as could the relative
release rates of diﬀerent granule pools, containing newly
synthesized versus previously synthesized GH [16]. It is
howeverimportanttonotethatdiﬀerencesinthesensitivities
of the 20 and 22K-hGH assays may also impact on these
results with the larger decline in 22K-hGH which was
detected possibly reﬂecting the diﬀerence between these two
assaysespeciallyatvaluesclosetothelimitofdetectionofthe
assay.
Although the biological eﬀects of these changes may
be insigniﬁcant, these observations nevertheless have impli-
cations for interpreting provocative GH testing in clinical
practice. Many guidelines for testing the GH axis suggestInternational Journal of Pediatric Endocrinology 5
that more than one test is undertaken [1]. In many clinical
situations it is convenient to combine tests so that the two
testsmaybeappliedconsecutively.Leavingasidewhetherthis
is statistically valid or not [17] there is the potential problem
that the “cut-oﬀ” used to deﬁne normality on the second
test should not necessarily be the same as that used for the
ﬁrst, especially if the components of what is being measured
is changing between tests. With an increasing move towards
monoclonal GH immunoassays and calibration using 22K
biosynthetic hGH it is obvious that total bioactive GH
secretion will be greater than that estimated only for 22K-
hGH. This may become important in situations of poor
GHstorage(withinadequatesomatotroph mass)or constant
hyperstimulation, where both reduction in secretory reserve
and an increase in the proportion of 20K-hGH and other
isoforms, may rise as hGH rises. Our observations stress
the importance of considering the impact of chronic or
repetitive stimulation of the GH axis on the production of
GH bioactive forms that may escape detection in clinical
diagnostic tests that speciﬁcally measure only maximal 22K-
hGH secretion. These observations may have important
implications for the interpretation of clinical diagnostic tests
of the GH axis.
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